Cargando…

A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy

COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuttke, Matthias, Seidl, Maximilian, Malinoc, Angelica, Prischl, Friedrich C., Kuehn, E. Wolfgang, Walz, Gerd, Köttgen, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655797/
https://www.ncbi.nlm.nih.gov/pubmed/26613025
http://dx.doi.org/10.1093/ckj/sfv091
_version_ 1782402221329088512
author Wuttke, Matthias
Seidl, Maximilian
Malinoc, Angelica
Prischl, Friedrich C.
Kuehn, E. Wolfgang
Walz, Gerd
Köttgen, Anna
author_facet Wuttke, Matthias
Seidl, Maximilian
Malinoc, Angelica
Prischl, Friedrich C.
Kuehn, E. Wolfgang
Walz, Gerd
Köttgen, Anna
author_sort Wuttke, Matthias
collection PubMed
description COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt haematuria or hearing loss. A renal biopsy revealed features of atypical IgA nephropathy, while a second biopsy a year later showed features of focal segmental glomerulosclerosis, but was finally diagnosed as chronic thrombotic microangiopathy. Targeted sequencing of candidate genes for steroid-resistant nephrotic syndrome and congenital thrombotic microangiopathy was negative. Despite all therapeutic efforts, including angiotensin-converting enzyme inhibition, immunosuppressive therapy, plasma exchanges and rituximab, the patient progressed to end-stage renal disease. When a male cousin presented with nephrotic syndrome years later, whole-exome sequencing identified a shared disruptive COL4A5 mutation (p.F222C) that showed X-linked segregation. Thus, mutations in COL4A5 give rise to a broader spectrum of clinical presentation than commonly suspected, highlighting the benefits of comprehensive rather than candidate genetic testing in young patients with otherwise unexplained glomerular disease. Our results are in line with an increasing number of atypical presentations of single-gene disorders identified through genome-wide sequencing.
format Online
Article
Text
id pubmed-4655797
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-46557972015-11-26 A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy Wuttke, Matthias Seidl, Maximilian Malinoc, Angelica Prischl, Friedrich C. Kuehn, E. Wolfgang Walz, Gerd Köttgen, Anna Clin Kidney J Contents COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt haematuria or hearing loss. A renal biopsy revealed features of atypical IgA nephropathy, while a second biopsy a year later showed features of focal segmental glomerulosclerosis, but was finally diagnosed as chronic thrombotic microangiopathy. Targeted sequencing of candidate genes for steroid-resistant nephrotic syndrome and congenital thrombotic microangiopathy was negative. Despite all therapeutic efforts, including angiotensin-converting enzyme inhibition, immunosuppressive therapy, plasma exchanges and rituximab, the patient progressed to end-stage renal disease. When a male cousin presented with nephrotic syndrome years later, whole-exome sequencing identified a shared disruptive COL4A5 mutation (p.F222C) that showed X-linked segregation. Thus, mutations in COL4A5 give rise to a broader spectrum of clinical presentation than commonly suspected, highlighting the benefits of comprehensive rather than candidate genetic testing in young patients with otherwise unexplained glomerular disease. Our results are in line with an increasing number of atypical presentations of single-gene disorders identified through genome-wide sequencing. Oxford University Press 2015-12 2015-09-29 /pmc/articles/PMC4655797/ /pubmed/26613025 http://dx.doi.org/10.1093/ckj/sfv091 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Contents
Wuttke, Matthias
Seidl, Maximilian
Malinoc, Angelica
Prischl, Friedrich C.
Kuehn, E. Wolfgang
Walz, Gerd
Köttgen, Anna
A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title_full A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title_fullStr A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title_full_unstemmed A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title_short A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
title_sort col4a5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
topic Contents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655797/
https://www.ncbi.nlm.nih.gov/pubmed/26613025
http://dx.doi.org/10.1093/ckj/sfv091
work_keys_str_mv AT wuttkematthias acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT seidlmaximilian acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT malinocangelica acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT prischlfriedrichc acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT kuehnewolfgang acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT walzgerd acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT kottgenanna acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT wuttkematthias col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT seidlmaximilian col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT malinocangelica col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT prischlfriedrichc col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT kuehnewolfgang col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT walzgerd col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy
AT kottgenanna col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy